What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic analogue of the C-terminal fragment of human growth hormone (hGH176-191). Researchers study it for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) in a manner similar to full-length GH, but without the blood glucose-raising or muscle-building properties associated with complete GH.
Research Dosing Parameters
- Typical dose range: 250–500 mcg per injection
- Common vial size: 5 mg
- Reconstitution: 1–2 mL bacteriostatic water
- Injection frequency: Once daily in most research protocols, often in the morning
How to Reconstitute AOD-9604
- Inject bacteriostatic water slowly along the vial wall
- Gently swirl until the lyophilized powder dissolves completely
- Do not shake vigorously
- Store reconstituted vial at 2–8°C
- Use within 30 days
FAQ
Does AOD-9604 affect blood sugar like regular GH? Research suggests AOD-9604 does not significantly affect insulin sensitivity or blood glucose levels, unlike full-length growth hormone — making it a subject of interest for metabolic fat loss research.
Can AOD-9604 be combined with other peptides? AOD-9604 is sometimes studied alongside GHRH/GHRP combinations or peptides like CJC-1295 and ipamorelin. Use the multi-peptide feature in the calculator above.
What time of day is AOD-9604 typically administered? Research protocols typically administer AOD-9604 in a fasted state in the morning to take advantage of enhanced lipolytic conditions.